BioMarin said the FDA accepted a supplemental filing to convert VOXZOGO from accelerated to full approval for children with achondroplasia; PDUFA date is Feb. 28, 2027.

Brief internet outages hit the Bay Area on March 16, with Xfinity customers among those reporting dropouts and monitoring sites flagging wider spikes.

BioMarin will buy Amicus for roughly $4.8 billion, folding two marketed rare‑disease drugs into its portfolio as the companies eye a Q2 2026 close. The agreement is subject to shareholder and regulatory approvals.